When tested against BACE1 (β-site Amyloid precursor protein Cleaving Enzyme type 1), an enzyme implicated in Alzheimer’s disease, compound 40 was about 12- to 30-fold less active as an BACE1 inhibitor compared to cathepsins D and E [104]. The gene discussed is BACE1; the disease is Alzheimer disease.